Search Results - "Luis Calzadilla-Bertot"

The Natural Course of Non-Alcoholic Fatty Liver Disease by Calzadilla Bertot, Luis, Adams, Leon Anton

“…Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the world, paralleling the epidemic of obesity and Type 2…”
Get full text

Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand by Calzadilla‐Bertot, Luis, Jeffrey, Gary P., Jacques, Bryon, McCaughan, Geoffrey, Crawford, Michael, Angus, Peter, Jones, Robert, Gane, Edward, Munn, Stephen, Macdonald, Graeme, Fawcett, Jonathan, Wigg, Alan, Chen, John, Fink, Michael, Adams, Leon A.

“…The worldwide increase in obesity and diabetes has led to predictions that nonalcoholic steatohepatitis (NASH) will become the leading indication for…”
Get full text

ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver‐Related Cirrhosis by Calzadilla‐Bertot, Luis, Vilar‐Gomez, Eduardo, Wong, Vincent Wai‐Sun, Romero‐Gomez, Manuel, Aller‐de la Fuente, Rocio, Wong, Grace Lai‐Hung, Castellanos, Marlen, Eslam, Mohammed, Desai, Archita P., Jeffrey, Gary P., George, Jacob, Chalasani, Naga, Adams, Leon A.

“…Background and Aims Nonalcoholic fatty liver disease (NAFLD) is an increasingly important cause of liver cirrhosis and subsequent complications. We…”
Get full text

Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy‐proven NASH by Vilar‐Gomez, Eduardo, Calzadilla‐Bertot, Luis, Friedman, Scott L., Gra‐Oramas, Bienvenido, Gonzalez‐Fabian, Licet, Lazo‐del Vallin, Sacha, Diago, Moises, Adams, Leon A.

“…Background & Aims The dynamic response of serum fibrosis biomarkers to histological changes within the liver following lifestyle intervention (LI) is unknown…”
Get full text

Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention by Vilar‐Gomez, Eduardo, Yasells‐Garcia, Ali, Martinez‐Perez, Yadina, Calzadilla‐Bertot, Luis, Torres‐Gonzalez, Ana, Gra‐Oramas, Bienvenido, Gonzalez‐Fabian, Licet, Villa‐Jimenez, Oscar, Friedman, Scott L., Diago, Moises, Romero‐Gomez, Manuel

“…Liver biopsy is the gold standard method to assess nonalcoholic steatohepatitis (NASH) resolution after therapeutic interventions. We developed and validated a…”
Get full text

The natural history of compensated HCV-related cirrhosis: A prospective long-term study by Gomez, Eduardo Vilar, Rodriguez, Yoan Sanchez, Bertot, Luis Calzadilla, Gonzalez, Ana Torres, Perez, Yadina Martinez, Soler, Enrique Arus, Garcia, Ali Yasells, Blanco, Luis Perez

“…Background & Aims The natural history of HCV-related compensated cirrhosis has been poorly investigated in Latin-American countries. Our study evaluated…”
Get full text

Editorial: targeting liver biopsy in NAFLD – the need to expand non‐invasive tools by Calzadilla Bertot, Luis

“…LINKED CONTENT This article is linked to Kim et al papers. To view these articles, visit https://doi.org/10.1111/apt.16674 and https://doi.org/10.1111/apt.16711…”
Get full text

Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis by Gomez, Eduardo Vilar, Gonzalez, Ana Torres, Bertot, Luis Calzadilla, Yasells Garcia, Ali, Rodriguez, Yoan Sanchez, Perez, Yadina Martinez

“…Arterial blood pressure (BP) is a reliable marker of circulatory dysfunction in cirrhotic patients. There are no prospective studies evaluating the association…”
Get full text

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis by Vilar-Gomez, Eduardo, Martinez-Perez, Yadina, Calzadilla-Bertot, Luis, Torres-Gonzalez, Ana, Gra-Oramas, Bienvenido, Gonzalez-Fabian, Licet, Friedman, Scott L, Diago, Moises, Romero-Gomez, Manuel

“…Background & Aims It is not clear how weight loss affects histologic features of liver in patients with nonalcoholic steatohepatitis (NASH). We examined the…”
Get full text

Editorial: Crystalising the burden of steatotic liver disease by Bertot, Luis Calzadilla, Adams, Leon A.

“…LINKED CONTENT This article is linked to Schneider et al papers. To view these articles, visit https://doi.org/10.1111/apt.17958 and…”
Get full text

Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C by Gomez, Eduardo Vilar, Perez, Yadina Martinez, Sanchez, Hector Vega, Forment, Gretel Riveron, Soler, Enrique Arus, Bertot, Luis Calzadilla, Garcia, Ali Yasells, del Rosario Abreu Vazquez, Maria, Fabian, Licet Gonzalez

“…AIM:To investigate the efficacy of Viusid,a nutritional supplement,as an antioxidant and an immunomodulator in patients with chronic hepatitis C.METHODS:Sixty…”
Get full text

Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease by Bertot, Luis Calzadilla, Adams, Leon A

“…Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and is associated with hepatocellular carcinoma (HCC), the most…”
Get more information

Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review by Bertot, Luis Calzadilla, Sato, Masaya, Tateishi, Ryosuke, Yoshida, Haruhiko, Koike, Kazuhiko

“…Objectives Reported rates of major complications and mortality of radiofrequency ablation (RFA), microwave ablation (MWA) and percutaneous ethanol injection…”
Get full text

Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease by Gomez, Eduardo Vilar, Bertot, Luis Calzadilla, Oramas, Bienvenido Gra, Soler, Enrique Arus, Navarro, Raimundo Llanio, Elias, Javier Diaz, Jiménez, Oscar Villa, Abreu Vazquez, Maria del Rosario

“…AIM： To investigate the capability of a biochemical and clinical model, BioCliM, in predicting the survival of cirrhotic patients. METHODS： We prospectively…”
Get full text

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial by Vilar Gomez, Eduardo, Sanchez Rodriguez, Yoan, Torres Gonzalez, Ana, Calzadilla Bertot, Luis, Arus Soler, Enrique, Martinez Perez, Yadina, Yasells Garcia, Ali, Abreu Vazquez, Maria del Rosario

“…ObjectivesViusid is a nutritional supplement with recognised antioxidant and immunomodulatory properties which could have beneficial effects on…”
Get full text

Modelos pronósticos para la cirrosis hepática by Calzadilla Bertot, Luis, Vilar Gómez, Eduardo, Lincheta Enriquez, Laritza

“…Los modelos pronósticos representan un pilar importante en la evaluación de los pacientes con cirrosis hepática, sobre todo a la hora de tomar decisiones como…”
Get full text

The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages by Gomez, Eduardo Vilar, Bertot, Luis Calzadilla, Rodriguez, Yoan Sanchez, Gonzalez, Ana Torres, Perez, Yadina Martinez, Garcia, Ali Yasells

“…Purpose The clinical course of hepatitis C virus-related cirrhosis and its temporal progression across the different clinical stages has not been completely…”
Get full text

Model for End-Stage Liver Disease and liver cirrhosis-related complications by Bertot, Luis Calzadilla, Gomez, Eduardo Vilar, Almeida, Linnet Alonso, Soler, Enrique Arus, Perez, Luis Blanco

“…The Model for End-Stage Liver Disease (MELD) score has gained wide acceptance for predicting survival in patients undergoing liver transplantation. The…”
Get full text

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study by Vilar-Gomez, Eduardo, Calzadilla-Bertot, Luis, Wai-Sun Wong, Vincent, Castellanos, Marlen, Aller-de la Fuente, Rocio, Metwally, Mayada, Eslam, Mohammed, Gonzalez-Fabian, Licet, Alvarez-Quiñones Sanz, María, Conde-Martin, Antonio Felix, De Boer, Bastiaan, McLeod, Duncan, Hung Chan, Anthony Wing, Chalasani, Naga, George, Jacob, Adams, Leon A., Romero-Gomez, Manuel

“…Little is known about the natural course of nonalcoholic fatty liver disease (NAFLD) with advanced fibrosis. We describe long-term outcomes and evaluate the…”
Get full text

Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease by Calzadilla-Bertot, Luis, Jeffrey, Angus W., Jeffrey, Gary P.

Get full text